cas 2641451-75-2|| where to buy Methyl (3S)-1-[(2S)-3-(4-bromo-2-thiazolyl)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]hexahydro-3-pyridazinecarboxylate

製品名:Methyl (3S)-1-[(2S)-3-(4-bromo-2-thiazolyl)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]hexahydro-3-pyridazinecarboxylate

IUPAC Name:methyl (3S)-1-[(2S)-3-(4-bromo-1,3-thiazol-2-yl)-2-{[(tert-butoxy)carbonyl]amino}propanoyl]-1,2-diazinane-3-carboxylate

包装単位	有効在庫	価格（USD）	数量

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2641451-75-2 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:2641451-75-2; 分子式:C17H25BrN4O5S; 融点:-; SMILESコード:C([C@H](CC1=NC(Br)=CS1)NC(OC(C)(C)C)=O)(=O)N2N[C@H](C(OC)=O)CCC2; 密度:

: Thiazoles; Thiazoles are very important functional groups in medicinal chemistry. They act as ligands on a variety of biological matrices. Thiazoles are used in a wide range of therapeutic applications, such as antibacterial, antiretroviral, antifungal, antiallergic, antihypertensive, pain treatment, and to control symptoms of schizophrenia.

: RMC-7977; KRAS was once a notorious 'undruggable target' over the past few decades. Most cancers driven by KRAS mutations lack corresponding targeted drugs. Now, this dilemma is finally expected to be broken!
Revolution Medicines recently announced the publication of two peer-reviewed research papers in Nature. Two original papers highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in preclinical models of RAS-mutant pancreatic ductal adenocarcinoma (PDAC). The first paper demonstrates RMC-7977 successfully targets signaling by both mutant and wild-type forms of RAS to drive potent and durable inhibition of RAS-mutated cancers. The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC. Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), PDAC and colorectal cancer (CRC). RAS G12 mutations, such as G12D, G12V and G12C, predominate in human cancers. Approved KRAS-targeted cancer therapies target only one particular RAS mutation, KRAS G12C.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.